Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 12:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Everolimus Clear all
Completed Phase 2 Interventional Results available

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

NCT01229943
View directory record Official record
Conditions
Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor, Pancreatic Gastrinoma, Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2, Pancreatic Vipoma
Interventions
Bevacizumab, Everolimus, Octreotide Acetate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
388
States / cities
Mobile, Alabama • Anaheim, California • Antioch, California + 272 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Sep 23, 2026, 12:32 AM EDT
Completed Phase 3 Interventional Results available

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

NCT01120249
View directory record Official record
Conditions
Kidney Cancer
Interventions
everolimus, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
1,545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1002
States / cities
Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 609 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 23, 2026, 12:32 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD

NCT02451696
View directory record Official record
Conditions
Epilepsy, Tuberous Sclerosis Complex, Focal Cortical Dysplasia
Interventions
Everolimus
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
2 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Sep 23, 2026, 12:32 AM EDT
Active, not recruiting Phase 2 Interventional

Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer

NCT01141309
View directory record Official record
Conditions
Thyroid Cancer
Interventions
sorafenib with everolimus
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 23, 2026, 12:32 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma

NCT00323739
View directory record Official record
Conditions
Kidney Cancer
Interventions
bevacizumab, RAD001
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Fort Myers, Florida • Gainesville, Florida • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Sep 23, 2026, 12:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.

NCT02732119
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Everolimus, Exemestane
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
25
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 23, 2026, 12:32 AM EDT
Completed Phase 1 Interventional Results available

Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

NCT00426556
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Everolimus, Trastuzumab, Paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
11
States / cities
*see Various Departments*, California • Fountain Valley, California • Loma Linda, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2015 · Synced Sep 23, 2026, 12:32 AM EDT
Completed Phase 1 Interventional

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

NCT00574366
View directory record Official record
Conditions
Breast Cancer
Interventions
erlotinib, RAD001
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Sep 23, 2026, 12:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

NCT01275222
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
RAD001, Imatinib 600mg/day (Glevec is the brand name for imatinib), Imatinib 800mg/day (Glevec is the brand name for imatinib)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 23, 2026, 12:32 AM EDT
Active, not recruiting Phase 1 Interventional

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

NCT02321501
View directory record Official record
Conditions
ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, ROS1 Gene Rearrangement, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Ceritinib, Everolimus, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 23, 2026, 12:32 AM EDT
Active, not recruiting Phase 2 Interventional

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

NCT01217931
View directory record Official record
Conditions
Kidney Cancer
Interventions
Pazopanib, Bevacizumab, Everolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 23, 2026, 12:32 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Everolimus Beyond Progression

NCT02269670
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
everolimus, anastrozole, letrozole, tamoxifen citrate, fulvestrant, megestrol acetate
Drug
Lead sponsor
Emory University
Other
Eligibility
19 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 23, 2026, 12:32 AM EDT
Completed Not applicable Interventional Results available

Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.

NCT02010021
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Sep 23, 2026, 12:32 AM EDT
Completed Phase 1 Interventional

Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment

NCT00610948
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
panitumumab, everolimus, fluorouracil, leucovorin calcium, oxaliplatin
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 23, 2026, 12:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

NCT01281514
View directory record Official record
Conditions
Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Interventions
everolimus, carboplatin, pegylated liposomal doxorubicin hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Sep 23, 2026, 12:32 AM EDT
Completed Phase 1 Interventional

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

NCT01430572
View directory record Official record
Conditions
Advanced Cancers, Solid Tumors
Interventions
Pazopanib, Everolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Sep 23, 2026, 12:32 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer

NCT01427946
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
IPI-504, Everolimus
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Aurora, Colorado • Tampa, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Sep 23, 2026, 12:32 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)

NCT00651482
View directory record Official record
Conditions
Kidney Neoplasms, Kidney (Renal Cell) Cancer
Interventions
Everolimus, Bevacizumab
Drug
Lead sponsor
Sandy Srinivas
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 23, 2026, 12:32 AM EDT
Completed Phase 2 Interventional Results available

Everolimus for Children With Recurrent or Progressive Ependymoma

NCT02155920
View directory record Official record
Conditions
Recurrent Childhood Ependymoma
Interventions
Everolimus
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
2 Years to 21 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
4
States / cities
Stanford, California • New York, New York • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 23, 2026, 12:32 AM EDT
Terminated Phase 1 Interventional

Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT02254239
View directory record Official record
Conditions
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Everolimus, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 23, 2026, 12:32 AM EDT
Terminated Phase 2 Interventional Results available

Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery

NCT02031536
View directory record Official record
Conditions
Gastrinoma, Glucagonoma, Insulinoma, Liver Metastases, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma
Interventions
everolimus, placebo
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 23, 2026, 12:32 AM EDT
Not listed Not applicable Interventional

Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

NCT02015728
View directory record Official record
Conditions
Recurrent Childhood Brain Tumor
Interventions
Tumor biology testing, Temozolomide, Etoposide, Sorafenib, Everolimus, Erlotinib, Dasatinib
Device · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Month to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 23, 2026, 12:32 AM EDT
Completed Phase 1 Interventional

Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer

NCT01700400
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Everolimus, Pemetrexed, Carboplatin, Bevacizumab
Drug
Lead sponsor
Cancer Research and Biostatistics Clinical Trials Consortium
Network
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Tuscon, Arizona • Lexington, Kentucky • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 23, 2026, 12:32 AM EDT
Completed Phase 1 Interventional

Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma

NCT01334502
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin hydrochloride, everolimus, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 23, 2026, 12:32 AM EDT